Xtant Medical Holdings, Inc.

Stage 4 · Declining · week 34

As of Oct 22, 2026, Xtant Medical Holdings is in Stage 4, the downtrend phase, now in week 34 (since Feb 26, 2026). It closed at $0.31, 66.3% below its 52-week high and below its 200-day average, which is falling.

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. More about the company

$0.31

+4.73% today

$43.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is XTNT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 45w

S2 14w

S4 34w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 11w → S3 4w → S2 8w → S3 7w → S4 45w → S1 9w → S4 7w → S1 2w → S2 10w → S3 8w → S2 14w → S3 6w → S4 34w current

Total tracked: 166 weeks across 13 stage runs.

XTNT among Medical Devices96th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…96	XTNTXtant Medical Holdings, Inc.	Stage 4 · wk 34	19	−18.4%

vs 52W High

-66.3%

$0.29 lo$0.92 hi

66.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 34

1w13w26w

Week 34, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-34.6%

200 DMA: $0.47 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.06x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.4%

-27.9%

-39.2%

YTD

-58.7%

-60.3%

Scan Membership

Breakout Watch

Latest: 2025-06-04

7 appearances in last 60 days. First seen: 2020-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 34 · Vol 0.06x

2026-10-21S4

Wk 33 · Vol 0.06x

2026-10-20S4

Wk 33 · Vol 0.04x

2026-10-19S4

Wk 33 · Vol 0.09x

2026-10-16S4

Wk 33 · Vol 0.05x

2026-10-15S4

Wk 33 · Vol 0.06x

2026-10-14S4

Wk 32 · Vol 0.04x

2026-10-13S4

Wk 32 · Vol 0.02x

2026-10-12S4

Wk 32 · Vol 0.02x

2026-10-09S4

Wk 32 · Vol 0.04x

2026-10-08S4

Wk 32 · Vol 0.03x

2026-10-07S4

Wk 31 · Vol 0.04x

Moving averages & range

50 DMA

$0.34

200 DMA

$0.47

52W High

$0.92

52W Low

$0.29

5D Low

$0.29

Resistance levels (recent highs)

20d High

$0.38

60d High

$0.45

120d High

$0.58

250d High

$0.92

Next resistance

+22.6%

to 20d High

ROE

-25.2%

Profit margin -10.2%

Dividend Yield

0.00%

P/B 1.1

Xtant Medical Holdings: quick answers

What stage is Xtant Medical Holdings in?

As of Oct 22, 2026, Xtant Medical Holdings (XTNT) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 26, 2026 and is in week 34. What the four stages mean

Is Xtant Medical Holdings in an uptrend?

No. Xtant Medical Holdings is in a Stage 4 downtrend. It trades 34.6% below its 200-day average, which is falling.

How far is Xtant Medical Holdings from its 52-week high?

Xtant Medical Holdings closed at $0.31 on Oct 22, 2026, 66.3% below its 52-week high of $0.92. Its 52-week low is $0.29.

How has Xtant Medical Holdings performed over the past year?

As of Oct 22, 2026, Xtant Medical Holdings is down 60.3% over the past year and down 58.7% so far in 2026.

Which sector and industry is Xtant Medical Holdings in?

Xtant Medical Holdings is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.